Literature DB >> 8127014

Vancomycin redistribution: dosing recommendations following high-flux hemodialysis.

T A Pollard1, V Lampasona, S Akkerman, K Tom, M A Hooks, R E Mullins, B J Maroni.   

Abstract

Although increased vancomycin clearance has been reported with highly permeable hemodialysis membranes (such as polysulfone), failure to consider post-dialysis redistribution could lead to unnecessary dosage supplementation. In protocol 1, twelve hemodialysis patients admitted for vascular access thrombectomy received 15 mg/kg of vancomycin as surgical prophylaxis. Post-operatively, patients underwent high-flux hemodialysis (HFHD) for two hours using a Fresenius F-80 polysulfone dialyzer (QB = 417 +/- 49, QD = 800 ml/min). Vancomycin's intradialytic clearance increased 13-fold compared to the patient's endogenous clearance (120 +/- 59 vs. 9 +/- 8 ml/min, respectively) yet dialysate recovery indicated that only 17% of body stores were removed (179 +/- 70 mg). Although serum vancomycin levels decreased 33% during HFHD, vancomycin levels increased in all patients following dialysis and the post-rebound values reached 87% of the pre-dialysis concentration. In protocol 2, eight outpatients receiving maintenance HFHD with a F-80 dialyzer (Kt/V = 1.29 +/- 0.08) were given 20 mg/kg of vancomycin immediately following dialysis on Monday; pre- and post-levels were measured during the next three dialysis treatments. The predialysis serum vancomycin levels were > 7.5 micrograms/ml (9.7 +/- 1.0 micrograms/ml; range 8.0 to 11.0) in all patients the following Monday. Thus, vancomycin clearance is increased during HFHD, but redistribution post-HD minimizes changes in serum levels. We recommend a 20 mg/kg i.v. loading dose and subsequent doses of 15 mg/kg every seven days; to account for individual variability, weekly vancomycin levels should be drawn before dialysis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8127014     DOI: 10.1038/ki.1994.28

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  10 in total

Review 1.  Pharmacokinetic optimisation of vancomycin therapy.

Authors:  W G Leader; M H Chandler; M Castiglia
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

2.  Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.

Authors:  Megan E DelDot; Jeffrey Lipman; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

3.  Predicting Maintenance Doses of Vancomycin for Hospitalized Patients Undergoing Hemodialysis.

Authors:  Wasim S El Nekidy; Maher M El-Masri; Greg S Umstead; Michelle Dehoorne-Smith
Journal:  Can J Hosp Pharm       Date:  2016-10-31

4.  Factors influencing vancomycin loading dose for hospitalized hemodialysis patients: prospective observational cohort study.

Authors:  Wasim S El Nekidy; Maher M El-Masri; Greg S Umstead; Michelle Dehoorne-Smith
Journal:  Can J Hosp Pharm       Date:  2012-11

5.  Treatment of paediatric vancomycin intoxication: a case report and review of the literature.

Authors:  Mathieu Lemaire; Bairbre Connolly; Elizabeth Harvey; Christoph Licht
Journal:  NDT Plus       Date:  2010-03-17

6.  Pharmacokinetics of Vancomycin in Pediatric Patients Receiving Intermittent Hemodialysis or Hemodiafiltration.

Authors:  Erin Chung; James A Tjon; Rosaleen M Nemec; Nadya Nalli; Elizabeth A Harvey; Christoph Licht; Winnie Seto
Journal:  Kidney Int Rep       Date:  2021-02-06

Review 7.  Clinical review: use of vancomycin in haemodialysis patients.

Authors:  Vincent Launay-Vacher; Hassane Izzedine; Lucile Mercadal; Gilbert Deray
Journal:  Crit Care       Date:  2002-06-10       Impact factor: 9.097

8.  PK/PD analysis of biapenem in patients undergoing continuous hemodiafiltration.

Authors:  Gaku Akashita; Yuto Hosaka; Toru Noda; Kazuya Isoda; Tsutomu Shimada; Kazuki Sawamoto; Ken-Ichi Miyamoto; Takumi Taniguchi; Yoshimichi Sai
Journal:  J Pharm Health Care Sci       Date:  2015-11-14

9.  In vivo evaluation of drug dialyzability in a rat model of hemodialysis.

Authors:  Masaki Fukunaga; Daisuke Kadowaki; Mika Mori; Satomi Hagiwara; Yuki Narita; Junji Saruwatari; Ryota Tanaka; Hiroshi Watanabe; Keishi Yamasaki; Kazuaki Taguchi; Hiroki Ito; Toru Maruyama; Masaki Otagiri; Sumio Hirata
Journal:  PLoS One       Date:  2020-06-12       Impact factor: 3.240

10.  Evaluation of Factors which Influence Mortality in Gram-positive Bacteremia in Hemodialysis Patients.

Authors:  Kerry Anne Rambaran; Saeed K Alzghari; Charles F Seifert
Journal:  Cureus       Date:  2018-07-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.